Mecolzine (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the gut mucosa, which reduces the production of prostaglandins and leukotrienes—key mediators of inflammation. This localized action diminishes inflammatory cell activity and cytokine release, providing targeted relief without widespread immunosuppression.

The dosage of Mecolzine is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Healthcare professionals determine the appropriate strength, frequency, and duration, and patients should follow the prescription label exactly.

Safety data for mesalazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before using Mecolzine.

To request Mecolzine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to mesalazine is sulfasalazine, which also delivers 5‑aminosalicylic acid but includes a sulfapyridine moiety that can cause more systemic side effects. Mesalazine generally offers a better tolerability profile because it lacks the sulfapyridine component, though both aim to control IBD inflammation.

Mecolzine should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Mecolzine is taken orally, usually with a full glass of water. It can be swallowed with or without food, but patients should follow the specific instructions on the prescription label regarding timing relative to meals.

Serious adverse events, although rare, include myocarditis, severe skin reactions such as Stevens‑Johnson syndrome, blood dyscrasias like neutropenia, pancreatitis, hepatic dysfunction, and interstitial nephritis. Patients should seek immediate medical attention if they experience chest pain, unexplained rash, fever, jaundice, or changes in urine output.

Mecolzine is contraindicated in individuals with a known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and it is not recommended for use in children unless specifically prescribed by a pediatric specialist.